These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 30755255)

  • 1. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
    Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
    Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
    Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
    Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
    Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
    PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial.
    Wunderlich G; Blahova Z; Garcia M; Jessen F
    Alzheimers Res Ther; 2023 Jan; 15(1):24. PubMed ID: 36709275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.
    Koh SH; Kwon HS; Choi SH; Jeong JH; Na HR; Lee CN; Yang Y; Lee AY; Lee JH; Park KW; Han HJ; Kim BC; Park JS; Lee JY; Kim S; Lee KY
    Alzheimers Res Ther; 2021 Mar; 13(1):66. PubMed ID: 33771205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
    Gauthier S; Feldman HH; Schneider LS; Wilcock GK; Frisoni GB; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Wischik DJ; Schelter BO; Davis CS; Staff RT; Bracoud L; Shamsi K; Storey JM; Harrington CR; Wischik CM
    Lancet; 2016 Dec; 388(10062):2873-2884. PubMed ID: 27863809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
    Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
    Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
    Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
    Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
    McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
    J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.